Off-label uses of Bevacizumab: breast and lung cancer indications
BlueCross BlueShield Association
Record ID 32007000053
English
Authors' objectives:
This assessment summarizes and evaluates evidence on outcomes of bevacizumab for breast cancer and non-small cell lung cancer (NSCLC). For both cancers, evidence on bevacizumab is assessed separately as second- or subsequent-line therapy for advanced or metastatic disease, as first-line therapy for advanced or metastatic disease, or as adjuvant therapy for early stage disease. Another Assessment (Vol. 21, No. 9) summarizes and evaluates evidence on health outcomes of bevacizumab for clear cell renal carcinoma and other malignancies besides colorectal cancers.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antibodies, Monoclonal
- Breast Neoplasms
- Lung Neoplasms
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.